top of page

European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma

Autorenbild: nuaxia
nuaxia
27. Okt.
2 Min. Lesezeit

The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting.


Tecvayli (teclistamab) is now authorised in the European Union as monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy, expanding its use beyond later-line treatment.


In the Phase III MajesTEC-9 study, teclistamab reduced the risk of disease progression or death by 71% and the risk of death by 40% compared with standard-of-care regimens, supporting its use from the second-line setting.

Field

Content

Article Type

Approvals

Regulatory Authority

European Commission

Regulatory Decision

Marketing authorisation indication extension

Announcement Date

23 October 2026

Company

Johnson & Johnson

Drug Name

Tecvayli

Generic Name

Teclistamab

Therapeutic Modality

Bispecific antibody

Therapeutic Area

Haematology; oncology

Approved Indication

Monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy

Patient Population

Adults with relapsed or refractory multiple myeloma

Minimum Prior Treatment

At least one prior therapy

Treatment Setting

From first relapse; second-line and later

Treatment Regimen

Tecvayli monotherapy

Supporting Clinical Study

Phase III MajesTEC-9

Comparator

Standard-of-care regimens

Progression or Death Risk Reduction

71% relative risk reduction

Death Risk Reduction

40% relative risk reduction

Geography

European Union

Previous Regulatory Context

Tecvayli was previously authorised in later-line multiple myeloma settings; this monotherapy extension is distinct from the Tecvayli plus daratumumab approval

What Happened

The European Commission expanded Tecvayli's monotherapy indication to adults with relapsed or refractory multiple myeloma after at least one prior treatment.

Why It Matters

The decision makes a bispecific antibody treatment option available earlier in the European multiple myeloma care pathway.

Clinical Evidence

MajesTEC-9 reported a 71% reduction in progression or death risk and a 40% reduction in death risk versus standard-of-care regimens.

Key Takeaway

Tecvayli monotherapy can now be used from first relapse in eligible EU patients, supported by Phase III evidence.

What to Watch

European reimbursement decisions, treatment sequencing, specialist centre adoption, safety management and long-term outcomes.

Primary Source

Johnson & Johnson Innovative Medicine

Primary Source URL

https://www.jnj.com/innovativemedicine/emea/media-center/press-releases/european-commission-approves-johnson-johnsons-tecvayli-teclistamab-monotherapy-for-relapsed-refractory-multiple-myeloma-expanding-treatment-options-from-first-relapse

Relevant Date

23 October 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

Kommentare

Mit 0 von 5 Sternen bewertet.
Noch keine Ratings

Rating hinzufügen
bottom of page